BACKGROUND: Tacrolimus (Tac) is a macrolide immunosuppressant drug isolated from Streptomyces tsukubaensis, widely used in organ transplantation. OBJECTIVE: This study examined the effect of tacrolimus administered by oral route (p.o.) on inflammation in mouse subcutaneous air pouch triggered by carrageenan (Cg 1%). METHODS: The air pouch was induced as described by Benincá et al. [Benincá JP, Montanher AB, Zucolotto SM, Schenkel EP, FrödeTS. Anti-inflammatory effects of the Passiflora edulis: forma flavicarpa Degener inhibition of leukocytes, enzymes and pro-inflammatory cytokine levels in the air pouch model, in mice. Food Chem 2007; 104(3); 1097-1105.]. The inflammatory parameters (leukocytes, exudation, myeloperoxidase (MPO) and adenosine-deaminase (ADA) activities, as well as nitrate/nitrate concentrations (NO(x)), interleukin-1 beta (IL-1beta), chemokine to neutrophil (KC) and tumor necrosis factor-alpha (TNF-alpha) levels were analysed 24 h after injection of carrageenan. RESULTS: Tacrolimus, indomethacin and dexamethasone significantly inhibited leukocytes, neutrophils and exudation (P<0.05) when they were administered 0.5 h before inflammation. These drugs, under the same conditions, decreased MPO and ADA activities (P<0.05), NO(x) and IL-1beta levels (P<0.01). Tacrolimus and indomethacin, but not dexamethasone, inhibited KC levels (P<0.01). On the other hand, tacrolimus and dexamethasone, but not indomethacin, decreased TNF-alpha levels (P<0.01). CONCLUSIONS: Results of this study indicate that tacrolimus has an important anti-inflammatory property, showing not only inhibition of pro-inflammatory mediators release, but also inhibition of activated leukocyte infiltration into the site of inflammation. Furthermore, these results showed that most of the anti-inflammatory actions of tacrolimus were similar to those observed in animals treated with either indomethacin or dexamethasone.
BACKGROUND:Tacrolimus (Tac) is a macrolide immunosuppressant drug isolated from Streptomyces tsukubaensis, widely used in organ transplantation. OBJECTIVE: This study examined the effect of tacrolimus administered by oral route (p.o.) on inflammation in mouse subcutaneous air pouch triggered by carrageenan (Cg 1%). METHODS: The air pouch was induced as described by Benincá et al. [Benincá JP, Montanher AB, Zucolotto SM, Schenkel EP, FrödeTS. Anti-inflammatory effects of the Passiflora edulis: forma flavicarpa Degener inhibition of leukocytes, enzymes and pro-inflammatory cytokine levels in the air pouch model, in mice. Food Chem 2007; 104(3); 1097-1105.]. The inflammatory parameters (leukocytes, exudation, myeloperoxidase (MPO) and adenosine-deaminase (ADA) activities, as well as nitrate/nitrate concentrations (NO(x)), interleukin-1 beta (IL-1beta), chemokine to neutrophil (KC) and tumor necrosis factor-alpha (TNF-alpha) levels were analysed 24 h after injection of carrageenan. RESULTS:Tacrolimus, indomethacin and dexamethasone significantly inhibited leukocytes, neutrophils and exudation (P<0.05) when they were administered 0.5 h before inflammation. These drugs, under the same conditions, decreased MPO and ADA activities (P<0.05), NO(x) and IL-1beta levels (P<0.01). Tacrolimus and indomethacin, but not dexamethasone, inhibited KC levels (P<0.01). On the other hand, tacrolimus and dexamethasone, but not indomethacin, decreased TNF-alpha levels (P<0.01). CONCLUSIONS: Results of this study indicate that tacrolimus has an important anti-inflammatory property, showing not only inhibition of pro-inflammatory mediators release, but also inhibition of activated leukocyte infiltration into the site of inflammation. Furthermore, these results showed that most of the anti-inflammatory actions of tacrolimus were similar to those observed in animals treated with either indomethacin or dexamethasone.
Authors: Mariana Angelica Oliveira Bitencourt; Gracielle Rodrigues Dantas; Daysianne Pereira Lira; Jose Maria Barbosa-Filho; George Emmanuel Cavalcanti de Miranda; Barbara Viviana de Oliveira Santos; Janeusa Trindade Souto Journal: Mar Drugs Date: 2011-08-10 Impact factor: 6.085
Authors: Marília Maria Sitônio; Carlson H R de Carvalho Júnior; Ingrid de A Campos; José Bruno Nunes Ferreira Silva; Maria do Carmo Alves de Lima; Alexandre J S Góes; Maria Bernadete Sousa Maia; Pedro J Rolim Neto; Teresinha G Silva Journal: Inflamm Res Date: 2012-09-28 Impact factor: 6.986
Authors: Mariana Martins Gomes Pinheiro; Ana B Miltojević; Niko S Radulović; Ikarastika Rahayu Abdul-Wahab; Fabio Boylan; Patrícia Dias Fernandes Journal: PLoS One Date: 2015-03-25 Impact factor: 3.240
Authors: Manoela Torres-Rêgo; Allanny Alves Furtado; Mariana Angélica Oliveira Bitencourt; Maira Conceição Jerônimo de Souza Lima; Rafael Caetano Lisbôa Castro de Andrade; Eduardo Pereira de Azevedo; Thaciane da Cunha Soares; José Carlos Tomaz; Norberto Peporine Lopes; Arnóbio Antônio da Silva-Júnior; Silvana Maria Zucolotto; Matheus de Freitas Fernandes-Pedrosa Journal: BMC Complement Altern Med Date: 2016-08-05 Impact factor: 3.659
Authors: W J A Banukie N Jayasuriya; Shiroma M Handunnetti; Chandanie A Wanigatunge; Gita H Fernando; D Thusitha U Abeytunga; T Sugandhika Suresh Journal: Evid Based Complement Alternat Med Date: 2020-03-05 Impact factor: 2.629